The differential distributions of CD8+ T cells, Tfh cells, and Th17 cells associating with the prognosis of HNSCC patients with high or low expression of PRAS40 solidified our conclusion that PRAS40 could be a tumor suppressor in HNSCC patients. The gene discussed is CD8A; the disease is neoplasm.